comprehensive -WSS

comprehensive

author：leisure time 2025-09-28 00:50:00 - browse：62

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Prime Medicine, Myeloid Therapeutics clash over genome

WSS

Why health care costs have stayed mostly flat since 2010

Keeping primary care docs in field isn't impossible, says AAFP CEO

Albert Bourla of Pfizer: worst biopharma CEO of 2023

STAT wants to know your pick for a great summer read or listen

The most pressing bird flu mysteries scientists want answered

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

entertainment

comprehensive

focus

At least 13 dead in Texas as scorching temps continue

Illumina board agrees to spin off Grail, as divestment plans proceed

Duchenne breakthrough therapy leaves behind pioneering families

STAT wants to know your pick for a great summer read or listen

The cancer drug shortage isn’t new — and neither are the solutions

A new initiative will help leaders fight the next pandemic

Medical records are filled with copy

Prime Medicine, Myeloid Therapeutics clash over genome

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Can sheer will power keep patients alive in their dying hours?

focus

Fight over Supreme Court dialysis ruling puts kidney patients at risk

STAT wants to know your pick for a great summer read or listen

David Ricks of Eli Lilly: best biopharma CEO of 2023

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Eli Lilly’s Zepbound improved liver scarring in mid

leisure time

knowledge

explore

focus